Nosocomial infection and characterization of extended-spectrum β-lactamases-producing enterobacteriaceae in Northeast Brazil;Infeccao hospitalar e caracterizacao de enterobacterias produtoras de β-lactamases de espectro ampliado no Nordeste do Brasil

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 44, Issue 4, 2011, Pages 441-446

  Abreu, Afonso Gomes ^a   Marques, Sirlei Garcia ^b   Monteiro Neto, Valério ^a,c   de Carvalho, Roberto Morais Luz ^a   Gonçalves, Azizedite Guedes ^a  

^a FEDERAL UNIVERSITY OF MARANHÃO   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c CEUMA UNIVERSITY   (Brazil)

Author keywords

Antimicrobial resistance; Enterobacteriaceae; ESBLs; Nosocomial infection

Indexed keywords

AMIKACIN; AMPICILLIN; AZTREONAM; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLAVULANIC ACID; COTRIMOXAZOLE; ERTAPENEM; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM DETECTION; BACTERIUM ISOLATE; BLA GENE; BRAZIL; CONTROLLED STUDY; DISK DIFFUSION; ENTEROBACTERIACEAE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; HOSPITAL INFECTION; KLEBSIELLA PNEUMONIAE; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PREVALENCE;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BRAZIL; CROSS INFECTION; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PHENOTYPE;

ENTEROBACTERIACEAE; ESCHERICHIA COLI; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; PROTEUS MIRABILIS;

EID: 81455155760     PISSN: 00378682     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0037-86822011000400008     Document Type: Article

References (35)

1. Khanfar HS, Bindayna KM, Senok AC, Botta GA. Extended-spectrum betalactamases (ESBLs) in Escherichia coli and Klebsiella pneumoniae: trends in the hospital and community settings. J Infect Dev Ctries 2009; 3:295-299.
2. Mendelson G, Hait V, Ben-Israel J, Gronish D, Granot E, Raz R. Prevalence and risk factors of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in an Israeli long-term care facility. Eur J Clin Microbiol Infect Dis 2005; 24:17-22.
3. Minarini LAR, Gales AC, Palazzo ICV, Darini ALC. Prevalence of Community- Occurring Extended Spectrum β-Lactamase-Producing Enterobacteriaceae in Brazil. Curr Microbiol 2007; 54:335-341.
4. Bradford PA. Extended-spectrum-β-lactamases in the 21st century: caracterização, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14:933-951.
5. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 2005; 18:657-686.
6. Sader HS, Gales AC, Pfaller MA, Mendes RE, Zoccoli C, Barth A, et al. Pathogen frequency and resistance patterns in brazilian hospitals: summary of results from three years of the SENTRY Antimicrobial Surveillance Program. Braz J Infect Dis 2001; 5:200-214.
7. Freitas ALP, Machado DP, Soares FS, Barth AL. Extended-Spectrum β-lactamases in Klebsiella spp. and Escherichia coli obtained in a Brazilian teaching Hospital: detection, prevalence and molecular typing. Braz J Microbiol 2003; 34:344-348.
8. Jones RN, Pfaller MA. Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with extended-spectrum β-lactamases in Europe. Clin Microbiol Inf 2003; 9:708-712.
9. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: eighteenth informational supplement. CLSI document M100-S18. Wayne (PA), USA: CLSI; 2008.
10. blaCTX-M genes in Enterobacteriaceae. APMIS 2007; 115:1400-1408.
11. Kiratisin P, Apisarnthanarak A, Laesripa C, Saifon P. Molecular Characterization and Epidemiology of Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Isolates Causing Health Care-Associated Infection in Thailand, Where the CTX-M Family is Endemic. Antimicrob Agents Chemother 2008; 52:2818-2824.
12. Mendes C, Hsiung A, Kiffer C. Evaluation of the in vivo Activity of Antimicrobials Against Bacterial Strains Isolated from Patients in Intensive Care Units in Brazil: MYSTIC Antimicrobial Surveillance Program. Braz J Infect Dis 2000; 4:236-244.
13. Nogueira KS, Higuti IH, Nascimento AJ, Terasawa LB, Oliveira S, Matos AP, et al. Occurrence of Extended-Spectrum Beta-lactamases in Enterobacteriaceae Isolated from Hospitalized Patients in Curitiba, Southern Brazil. Braz J Infect Dis 2006; 10:390-395.
14. Empel J, Baraniak A, Literacka E, Mrówka A, Fiett J, Sadowy E, et al. Molecular Survey of β-Lactamases Conferring Resistance to Newer b-Lactams in Enterobacteriaceae Isolates from Polish Hospitals. Antimicrob Agents Chemother 2008; 52:2449-2454.
15. Luzzaro F, Mezzatesta M, Mugnaioli C, Perilli M, Stefani S, Amicosante G, et al. Trends in Production of Extended-Spectrum b-Lactamases among Enterobacteria of Medical Interest: Report of the Second Italian Nationwide Survey. J Clin Microbiol 2006; 44:1659-1664.
16. Galas M, Decousser J, Breton N, Godard T, Allouch PY, Pina P. Nationwide Study of the Prevalence, Characteristics, and Molecular Epidemiology of Extended- Spectrum β-Lactamase-Producing Enterobacterieceae in France. Antimicrob Agents Chemother 2008; 52:786-789.
17. Menashe G, Borer A, Yagupsky P, Peled N, Gilad J, Fraser D, et al. Clinical significance and impact on mortality of extended-spectrum beta lactamaseproducing Enterobacteriaceae isolates in nosocomial bloodstream infections. Scand J Infect Dis 2001; 33:188-193.
18. Superti SV, Augusti G, Zavascki AP. Risk factors for and mortality of extendedspectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli nosocomial bloodstream infections. Rev Inst Med Trop São Paulo 2009; 51:211-216.
19. Turner PJ. Extended-spectrum β-lactamase. Clin Infect Dis 2005; 41:273-275.
20. Gales AC, Sader HS, Jones RN. Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin American: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Micr Infect Dis 2002; 44:301-311.
21. Schwaber MJ, Raney PM, Rasheed JK, Biddle JW, Williams P, McGowan JE, et al. Utility of NCCLS Guidelines for Identifying Extended-Spectrum β-Lactamases in Non-Escherichia coli and Non-Klebsiella spp. of Enterobacteriaceae. J Clin Microbiol 2004; 42:294-298.
22. Akpaka PE, Swanston WH. Phenotypic detection and occurrence of extendedspectrum beta-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli at a tertiary hospital in Trinidad & Tobago. J Infect Dis 2008; 12:516-520.
23. Pfaller MA, Segreti J. Overview of the epidemiological profile and laboratory detection of extended-spectrum beta-lactamases. Clin Infect Dis 2006; 42:153-163.
24. Silva N, Oliveira M, Bandeira AC, Brites C. Risk factors for infection by extendedspectrum beta-lactamases producing Klebsiella pneumoniae in Salvador, Brazil. Braz J Infect Dis 2006; 10:191-193.
25. Denton M. Enterobacteriaceae. Int J Antimicrob Ag 2007; 3:9-22.
26. McGowan AP. Clinical implications of antimicrobial resistance for therapy. J Antimicrob Chemother 2008; 62:105-114.
27. Murthy R. Implementation of strategies to control antimicrobial resistance. Chest 2003; 119:405-411.
28. Bonnet R, Dutour C, Sampaio JLM, Chanal C, Sirot D, Labia R, et al. Novel cefotaximase (CTX-M-16) with increased catalytic efficiency due to substitution Asp-2403Gly. Antimicrob Agents Chemother 2001; 45:2269-2275.
29. Livermore DM, Brown DFJ. Detection of β-lactamases-mediated resistance. J Antimicrob Chemother 2001; 48:59-64.
30. Pitout JDD, Church DL, Gregson DB, Chow BL, McCracken M, Mulvey MR, et al. Molecular epidemiology of CTX-M-producing Escherichia coli in the Calgary Health Region: emergence of CTX-M-15-producing isolates. Antimicrob Agents Chemother 2007; 51:1281-1286.
31. Canton R, Coque TM. The CTX-M b-lactamase pandemic. Curr Opin Microbiol 2006; 9:466-475.
32. Bonnet R, Sampaio JLM, Labia R, Champs C, Sirot D, Chanal C, et al. A novel CTX-M b-lactamase (CTX-M-8) in cefotaxime resistant Enterobacteriaceae isolated in Brazil. Antimicrob Agents Chemother 2000; 44:1936-1942.
33. Fang H, Ataker F, Hedin G, Dornbusch K. Molecular epidemiology of extendedspectrum beta-lactamases among Escherichia coli isolates collected in a Swedish hospital and its associated health care facilities from 2001 to 2006. J Clin Microbiol 2008; 46:707-712.
34. Lewis JS, Herrera M, Wickes B, Patterson JE, Jorgensen JH. First Report of the Emergence of CTX-M-Type Extended-Spectrum β-Lactamases (ESBLs) as the Predominant ESBL Isolated in a U.S. Health Care System. Antimicrob Agents Chemother 2007; 51:4015-4021.
35. Tofteland S, Haldorsen B, Dahl KH, Simonsen GS, Steinbakk M, Walsh TR, et al. Effects of Phenotype and Genotype on Methods for Detection of Extended- Spectrum-β-Lactamase-Producing Clinical Isolates of Escherichia coli and Klebsiella pneumoniae in Norway. J Clin Microbiol 2007; 45:199-205.